• Product nameAnti-BRG1 antibody [EPR3912]
    See all BRG1 primary antibodies
  • Description
    Rabbit monoclonal [EPR3912] to BRG1
  • Tested applicationsSuitable for: ICC/IF, WB, IHC-Pmore details
    Unsuitable for: Flow Cyt or IP
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (Human)

  • Positive control
    • WB: K562 or Molt-4 cell lysate; ICC/IF: HeLa cells; IHC-P: colon tissue.
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.


    Alternative versions available:

    Anti-BRG1 antibody (Alexa Fluor® 647) [EPR3912] (ab206598)

    Anti-BRG1 antibody (Alexa Fluor® 488) [EPR3912] (ab206712)



Our Abpromise guarantee covers the use of ab108318 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/250.
WB 1/1000 - 1/5000. Predicted molecular weight: 185 kDa.
IHC-P 1/100 - 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. Heat up to 98 degrees C, below boiling, and then let cool for 10-20 min.
  • Application notesIs unsuitable for Flow Cyt or IP.
  • Target

    • FunctionTranscriptional coactivator cooperating with nuclear hormone receptors to potentiate transcriptional activation. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP. Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a post-mitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to post-mitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth. SMARCA4/BAF190A may promote neural stem cell self-renewal/proliferation by enhancing Notch-dependent proliferative signals, while concurrently making the neural stem cell insensitive to SHH-dependent differentiating cues (By similarity). Also involved in vitamin D-coupled transcription regulation via its association with the WINAC complex, a chromatin-remodeling complex recruited by vitamin D receptor (VDR), which is required for the ligand-bound VDR-mediated transrepression of the CYP27B1 gene. Acts as a corepressor of ZEB1 to regulate E-cadherin transcription and is required for induction of epithelial-mesenchymal transition (EMT) by ZEB1.
    • Tissue specificityColocalizes with ZEB1 in E-cadherin-negative cells from established lines, and stroma of normal colon as well as in de-differentiated epithelial cells at the invasion front of colorectal carcinomas (at protein level).
    • Involvement in diseaseDefects in SMARCA4 are the cause of rhabdoid tumor predisposition syndrome type 2 (RTPS2) [MIM:613325]. RTPS2 is a familial cancer syndrome predisposing to renal or extrarenal malignant rhabdoid tumors and to a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumors. Rhabdoid tumors are the most aggressive and lethal malignancies occurring in early childhood.
    • Sequence similaritiesBelongs to the SNF2/RAD54 helicase family.
      Contains 1 bromo domain.
      Contains 1 helicase ATP-binding domain.
      Contains 1 helicase C-terminal domain.
      Contains 1 HSA domain.
    • Post-translational
      Phosphorylated upon DNA damage, probably by ATM or ATR.
    • Cellular localizationNucleus.
    • Information by UniProt
    • Database links
    • Alternative names
      • ATP dependent helicase SMARCA4 antibody
      • ATP-dependent helicase SMARCA4 antibody
      • BAF 190 antibody
      • BAF190 antibody
      • BAF190A antibody
      • Brahma protein like 1 antibody
      • BRG1 antibody
      • BRG1 associated factor 190A antibody
      • BRG1 protein antibody
      • BRG1-associated factor 190A antibody
      • BRM/SWI2 related gene 1 antibody
      • Global transcription activator homologous sequence antibody
      • global transcription activator snf2l4 antibody
      • Homeotic gene regulator antibody
      • hSNF2b antibody
      • Mitotic growth and transcription activator antibody
      • MRD16 antibody
      • Nuclear protein GRB1 antibody
      • Protein brahma homolog 1 antibody
      • Protein BRG-1 antibody
      • Protein BRG1 antibody
      • RTPS2 antibody
      • SMARC A4 antibody
      • SMARCA4 antibody
      • SMCA4_HUMAN antibody
      • SNF2 antibody
      • SNF2 beta antibody
      • SNF2 like 4 antibody
      • SNF2-beta antibody
      • SNF2B antibody
      • SNF2L4 antibody
      • SNF2LB antibody
      • Sucrose nonfermenting like 4 antibody
      • SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 4 antibody
      • SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 antibody
      • SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4 antibody
      • SWI2 antibody
      • Transcription activator BRG1 antibody
      see all

    Anti-BRG1 antibody [EPR3912] images

    • Predicted band size : 185 kDa
      Additional bands at : 185 kDa. We are unsure as to the identity of these extra bands.

      Lane 1: Wild-type HAP1 cell lysate (20 µg)

      Lane 2: BRG1 knockout HAP1 cell lysate (20 µg)

      Lane 3: K562 cell lysate (20 µg)

      Lane 4: Molt-4 cell lysate (20 µg)

      Lanes 1 - 4: Merged signal (red and green). Green - ab108318 observed at 1X kDa. Red - loading control, ab18058, observed at 124 kDa.

      ab108318 was shown to specifically react with BRG1 when BRG1 knockout samples were used. Wild-type and BRG1 knockout samples were subjected to SDS-PAGE. ab108318 and ab18058 (loading control to Vinculin) were diluted 1/1000 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

    • ab108318 at 1/100 staining BRG1 in paraffin-embedded Human colon tissue.
    • ab108318 at 1/100 staining BRG1 in HeLa cells by immunofluorescene.
    • All lanes : Anti-BRG1 antibody [EPR3912] (ab108318) at 1/1000 dilution

      Lane 1 : K562 cell lysate
      Lane 2 : Molt-4 cell lysate

      Lysates/proteins at 10 µg per lane.

      Predicted band size : 185 kDa
    • ab108318 showing positive staining in Urinary bladder transitional carcinoma tissue.

    • ab108318 showing positive staining in Breast carcinoma tissue.

    • ab108318 showing positive staining in Ovarian carcinoma tissue.

    • ab108318 showing positive staining in Normal tonsil tissue.

    References for Anti-BRG1 antibody [EPR3912] (ab108318)

    This product has been referenced in:
    • Vangamudi B  et al. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res 75:3865-78 (2015). Read more (PubMed: 26139243) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab108318.
    Please use the links above to contact us or submit feedback about this product.